Metyrapone for Mild Autonomous Cortisol Secretion (MACS)
Status:
Recruiting
Trial end date:
2028-01-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to find out whether the study drug, metyrapone, is safe and
effective in treating participants with Mild Autonomous Cortisol Secretion (MACS).